BMS has said in a statement that 14 abstracts will be presented
Singapore: The new clinical trial data and New Global Health Economics and Outcomes Research (GHEOR) analyses assessing cost effectiveness and real-world use to reinforce the alliance's commitment to the ongoing analysis of Eliquis in both the nonvalvular atrial fibrillation (NVAF) and venous thromboembolism (VTE).
BMS in a statement also said that 14 abstracts will be presented, including new analysis from the ARISTOTLE, AMPLIFY and AMPLIFY-EXT trials evaluating patients with NVAF and VTE.
